TickerTalks

Track every stock mention on X. Spot rising tickers before they're famous and validate the hype using our AI analysis. Research tool only - not financial advice

[TickerTalks @TickerTalksX]

By the time a stock is trending on your timeline, you're already late. Big runs start quietly. TickerTalks spots them first and notifies you.

→ Every ticker mention on X is tracked. Nothing slips past you.
→ The AI sentiment analysis on each name shows what the crowd's actually saying.
→ AI validates the hype against the hard numbers: earnings, filings, fundamentals.
→ Early spikes are flagged before they hit the headlines.

Stock research made easy - get started for free https://t.co/u5cB69nXR5

[TickerTalks @TickerTalksX]

$SE (Sea Limited) posted a record quarter: revenue up 46.6% YoY to $7.1B.

Shopee's orders grew 29%. Its core marketplace revenue grew 61%.

Revenue climbing twice as fast as order volume is the monetization story in one line: more ads, a higher take rate, the same number of people shopping.

[TickerTalks @TickerTalksX]

@TradexWhisperer That 8% month is a price move. Micron's HBM output is already sold out through 2026 on signed contracts. A year of the product driving the entire run is spoken for before it ships.

[TickerTalks @TickerTalksX]

The full read on the launch, the pipeline behind it, and what's kept the stock down:
https://t.co/0OXjdOeQO9

[TickerTalks @TickerTalksX]

Bronchiectasis is a chronic lung disease where the airways scar and widen, so mucus pools and infections keep coming back. Until last August, not a single drug was approved to treat it.

$INSM (Insmed) launched the first one, Brinsupri. In its first full quarter it did $207.9M, up 44% from the quarter before. Management guides it to at least $1B this year.

Total Q1 revenue hit $306M, up 230% from a year ago.

The stock is down about 39% in 2026.

[TickerTalks @TickerTalksX]

$KTOS (Kratos) builds the low-cost unmanned jets, the target drones that missile-defense systems train against, and the ground software that runs early-warning satellites. One layer under the Golden Dome missile shield everyone's talking about.

Last week it won a $446.8M Space Force contract to run the ground system for Resilient Missile Warning and Tracking, the program built to spot ICBM and hypersonic launches.

Q1 revenue: $371M, up ~23%. Backlog near $2B. Book-to-bill of 1.6.

Picks and shovels for the missile-defense buildout.

[TickerTalks @TickerTalksX]

@WhaleInsider Circle earns about 94% of its revenue as interest on the reserves behind USDC. Last quarter that was $653M of $694M, on roughly $77B in circulation. A G-SIB routing institutions to mint straight into that pool widens the funnel into the reserve base that is the business.

[TickerTalks @TickerTalksX]

Every dollar in an S&P 500 index fund tracks a number that one company owns and licenses out.

That company is $SPGI (S&P Global). It owns the S&P 500 and Dow Jones indexes, sits in the credit-ratings duopoly, and runs a slice of the market-data plumbing under Wall Street.

This week it spun off Carfax and its auto-data arm to become a purer index, ratings and data business. Around 70% gross margins, still growing double digits.

[TickerTalks @TickerTalksX]

Where $DLR sits in the AI-infrastructure stack, plus our latest read on it:
https://t.co/IAIwJbd6IS

[TickerTalks @TickerTalksX]

Powering and building a data center in Northern Virginia, the densest data-center market on earth, takes years of permits and grid hookups before a single server runs.

$DLR (Digital Realty) just skipped the wait. It bought Blackstone's majority stake in three finished ones there: 288 megawatts, already 100% leased to investment-grade hyperscalers on long-term contracts.

The assets are valued at $7.8B, at a cap rate north of 6.5%. Built capacity plus signed tenants, in one move.

[TickerTalks @TickerTalksX]

$AVAV (AeroVironment) Q4:

• Revenue $641.6M (+133% YoY), a record
• Adj. EPS $1.84 vs Est. $1.47
• Bookings $2.7B, 1.4x book-to-bill
• Funded backlog $1.2B
• FY27 revenue guide $2.13B–2.23B

The small-drone and loitering-munition maker just added a $500M counter-drone contract on top.

[TickerTalks @TickerTalksX]

The full breakdown on $ATEX, the spectrum model and the swing to profit:

https://t.co/zzAaY9oBCe

[TickerTalks @TickerTalksX]

The power grid is being wired up with sensors, smart meters and controls, and that needs a private wireless network utilities can actually rely on, not congested public cell towers. The airwaves for it sit in the 900 MHz band, which is licensed.

$ATEX (Anterix) owns that spectrum across the US and sells it to electric utilities one territory at a time. This year it signed $23.9M in new spectrum agreements with three utilities, has taken in $127M of contracted proceeds, carries no debt, and swung to a full-year profit. The stock is up roughly 4x over the past year.

A spectrum landlord for the grid buildout.

[TickerTalks @TickerTalksX]

@wliang The setup's real: Q1 bookings hit a record $102.1M, 1.21 book-to-bill. The humanoid slice is tiny so far, first humanoid orders were ~$1M. The rest is industrial and semiconductor-test demand, so the 270% YTD move is paying for Optimus optionality, not humanoid revenue yet.

[TickerTalks @TickerTalksX]

@amitisinvesting That $27B Meta deal is $12B committed capacity plus a $15B block Nebius can fill for Meta or resell to other AI cloud buyers. With capacity spoken for well ahead of delivery, an optional slug they can reprice looks more like leverage than the demand hole the tape priced in.

[TickerTalks @TickerTalksX]

Thyroid eye disease is a rare autoimmune condition that inflames the tissue behind the eyes and pushes them forward, causing bulging, double vision and pain. The standard treatment, Tepezza, is a blockbuster that takes eight IV infusions.

$VRDN (Viridian) just got FDA approval for Lumvoa and launched it the same day. Two differences that matter: five infusions instead of eight, and it's the first TED drug approved with data in both the active and the chronic form of the disease.

A more convenient, broader-label challenger walking straight into a market Tepezza built.

[TickerTalks @TickerTalksX]

$MAMA (Mama's Creations) makes the ready-to-eat meatballs, chicken and prepared meals that stock grocery deli counters. Most people have never heard of it. It's quietly building a one-stop deli supplier for national chains.

Q1 FY27:
• Revenue $52.8M, +50% YoY
• Net income $2.1M, +66%
• Adjusted EBITDA $4.9M, +71%

That 50% came while lapping a ~$10M one-time Costco order a year earlier. The prepared-deli category is fragmented and slow-growing. Mama's is consolidating the supply side of it, with a stated path to $1B revenue.

[TickerTalks @TickerTalksX]

@StockMKTNewz Today's ~10% drop is the market repricing AI hardware demand on Meta's cloud pivot, not Micron's own results. Last quarter it did $41.5B in revenue, up 346% YoY, at a record 84.9% gross margin. A demand-narrative selloff sitting on top of a record print.

[TickerTalks @TickerTalksX]

The full picture on $CELH: the growth, the acquisitions Q1 leaned on, and where the fundamentals land.
https://t.co/wFYPrmVWzQ

[TickerTalks @TickerTalksX]

One in five energy drinks sold in the US last quarter came from a $CELH (Celsius) brand: Celsius, Alani Nu, or Rockstar.

In 2020, Celsius was under 1% of the market. It bought its way to about 21% share by folding in Alani Nu and Rockstar, and Q1 revenue hit $782.6M, up 138% year over year.

The stock is down about 37% this year.

[TickerTalks @TickerTalksX]

All of $BIDU (Baidu) is worth about $35B today. Search, cloud, the Apollo Go robotaxi fleet, all of it.

Its AI-chip unit Kunlunxin, which Baidu controls with a roughly 58% stake, is reportedly filing to list in Hong Kong at a $50B valuation.

One subsidiary, valued higher than the entire parent that owns most of it. Investors were reportedly asked to buy Kunlunxin chips worth several times their share order just to get in.